

LONGITUDINAL COHORTS OF ALASKA NATIVE AND AMERICAN INDIAN PERSONS IN ALASKA WITH CHRONIC HEPATITIS B, HEPATITIS C

Lisa Townshend-Bulson, ANP

CDR, USPHS

Liver Disease & Hepatitis Program,

Division of Community Health Services

Alaska Native Tribal Health Consortium

Anchorage, AK

ANTHC Liver Disease & Hepatitis Program




©Ray Bulson

THE ALASKA TRIBAL HEALTH SYSTEM

Location Names and Service Level

- HOSPITALS
- MD HEALTH CENTERS
- PA/NP HEALTH CENTERS
- CHA CLINICS


Bold Face Names indicate that a higher level of Contract Health Care is available in that town.




Map provided by R. Hall
 Alaska Native Tribal Health Consortium
 Division of Health Information Technology
www.anthc.org
 2006

Hepatitis B in Alaska


Incidence of Symptomatic Hepatitis B in Alaska Native Persons 1981- 2008



Increasing Rates of Hepatitis C



Alaska HBV Cohort Characteristics




Characteristic	1691/1154 Consented N (%) or mean range)
Age (n = 1077 living)	48.2 years (20, 100)
Sex	Male 607 (56%) (Female 470 (44%)
Co-infections	HIV (n = 3, 1 living); Hepatitis C (n = 23, 15 living)
Required Treatment	189
Liver Biopsy	Patients (22%); 262 consented biopsied
Estimated Length of HBV Infection	28.97 years (0.4, 49.93)


Alaska HCV Cohort Characteristics

Characteristic	2525/1170 Consented N (%) or mean (range)
Age (n =1481 living)	50.9 years (16, 85)
Sex	Male 725 (49%) Female 756 (51%)
HCV Genotype 1112 genotyped	1 (65.6%); 2 (19.8%); 3 (14.1%); 4 (0.05%)
Co-infections	HIV (n = 41; 19 living); Hepatitis B (n = 23, 15 living)
Risk Behaviors	History of IVDU (57%) Blood Transfusion (20%)
% BMI ≥ 30	429/1213 (35%)
Treated for HCV	186 (14% of HCV RNA+)
Liver Biopsy	473 patients (35%); 762 biopsies (incl. multiple)
Estimated Length of HCV Infection	24.4 Years (1, 61)


Genotypes in HCV Cohort



Age Breakdown of HCV Cohort



IL28B Genotypes in HCV Cohort



95 participants tested

Peginterferon/Ribavirin

Treatment Results through 2011


Genotype	n	D/C'd	% D/C'd	# Completed Tx	Tx Failures	Relapsers	SVR	% SVR (I-T-T)	SVR in those able to finish tx
1	43	20	47%	23	10	3	10	23%	43%
2	37	7	19%	30	3	3	26	70%	81% *
3	20	7	35%	13	1	2	10	50%	77%
Total	100	34	34%	66	14	8	46	46%	68% *

*Includes 2 genotype 2s who did not finish tx but achieved SVR

Managing Patients With Chronic Hepatitis B and C from Afar

- Reminder letters about labs, US sent every 6 months
- Download of all hepatitis B and C labs sent to ANMC for review by program hepatologists, nurse practitioner
- Patients seen in hub sites at field clinics throughout the year
- Collection of sera on consented participants every 6-12 months for ongoing research
- LiverConnect for Provider Education, Case Studies

Letters, Newsletters To Encourage Follow-Up, Keep Cohort Up-to-Date



Hepatitis B & C Cohort Studies

- Natural History of Hepatitis B and C Infections
- Clearance of Hepatitis B Surface Antigen and Risk of HCC
- Hepatitis B Genotypes and Risk of HCC
- Adverse Outcomes of Persons Living With or Recovered from Hepatitis C
- Clinical Significance of AFP in Alaska Natives with Hepatitis C
- Hepatitis C Treatment Eligibility

Ongoing Projects

- Website Update- IHS Grant
<http://www.anthctoday.org/community/hep/index.html>
- LiverConnect Expansion
- Hepatitis C Cohort
 - Update on Clinical Outcomes through 2012
 - Proteomic markers of liver fibrosis
 - Treatment outcomes in AN/AI persons
- Hepatitis B Clinical Outcomes Studies
 - ALT/HBV DNA correlation with active vs. inactive hepatitis B
 - Chronic hepatitis B and diabetes
 - Immune markers of active vs. inactive chronic hepatitis B

Thank You!



©Ray Bulson